Clinical Trial Update: EFFECT OF A SUBSTANCE P ANTAGONIST ON THE SECRETION OF ALDOSTERONE IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA SYNDROME AND ARTERIAL HYPERTENSION [Phase 2]

View source ↗

Summary

A Phase 2 trial is investigating whether a Substance P antagonist affects aldosterone secretion in patients with obstructive sleep apnea and arterial hypertensi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension
• Obstructive Sleep Apnea

Drugs mentioned

• Substance P antagonist

Snippet

Sponsor: University Hospital, Rouen | Conditions: Apnea, Obstructive | Phase 2 | Status: RECRUITING